Data regarding the use of Interferon-gamma release assays (IGRAs) for tuberculosis diagnosis are accumulating. We systematically searched PubMed, EMBASE and Cochrane and performed pooled estimates of sensitivity and specificity of QuantiFERON-TB Gold In Tube (QFT-G-IT) and T-SPOT. TB compared to tuberculin skin test (TST). For studies assessing sensitivity, children had to have active tuberculosis. Specificity data were derived from children classified as non-infected. Eleven studies were included in the sensitivity analysis for TST, 10 for QFT-G-IT, and 9 for T-SPOT.TB. Eight studies were included in specificity analysis for TST, 8 for QFT-G-IT, and 7 for T-SPOT.TB. Pooled QFT-G-IT sensitivity was 0.79 (95%CI:0.70-0.89) pooled T-SPOT.TB sensitivity was 0.74 (95%CI:0.59-0.90) and pooled TST sensitivity was 0.82 (95%CI:0.72-0.93). Pooled QFT-G-IT and T-SPOT.TB specificities were 0.95 (95%CI:0.93-0.97) and 0.96 (95%CI:0.93-1.00), respectively. Pooled TST specificity was significantly lower 0.83 (95%CI:0.74-0.92). IGRA performance in children showed no better sensitivity than TST, but higher specificity.
adults, higher specificity ofIGRAs in respect to TST has been reported (5) (6) (7) (8) . The sensitivity for active TB ranges between 70-90% and is lower in high TB incidence settings (5) (6) (7) (8) . Thus, IGRAs are now included in diagnostic algorithms in adult guidelines (3) , but, to date, caution is recommended regarding their use in children (9) .
One previously published meta-analysis regarding IGRAs for the TB diagnosis in children found increased specificity of QFT-G compared to TST for the diagnosis of LTBI in children but sensitivity for TB disease was similar and reduced in studies conducted in high-TB incidence settings (1) . T-SPOT.TB performance was not evaluated. Hereby, we present the results of a systematic review and a meta-analysis on the performance of TST and IGRAs in children.
MATERIALSAND METHODS
A literature search was conducted using multiple keywords and standardized terminology in Medline, EMBASE and Cochrane databases dating back to their inception up to and through November 20th, 2010 (Appendix). The studies extracted were evaluated for eligibility for the meta-analysis on the basis of strict inclusion/exclusion criteria. Inclusion and exclusion criteria, Extraction of Data and Assessment of Study Quality are reported in Appendix.
Statistical methods
We computed sensitivity and specificity for each included study and calculated 95% confidence interval (95% CI) by an approximation to the Bernoulli distribution based on Fisher's F distribution (10) . In the meta-analysis sensitivity and specificity were pooled by the Der Simonian and Laird method using a random effects model to account for heterogeneity between studies (11). Cochran's Q test to test was used to assess homogeneity of sensitivity and specificity between studies (12) . The magnitude of heterogeneity between studies was expressed as the between study variance component, .2, and the variance proportion attributable to between studies heterogeneity, the F statistic (13) (14) (15) .
Additional analyses
Further analyses were performed to check how robust our findings were to model misspecification. Rather than using a single accuracy endpoint (sensitivity or specificity) per study, we used a multivariate meta-analysis model. We fitted a two-level mixed logistic regression model, with independent binomial distributions for the true positives and true negatives conditional on the sensitivity and specificity in each study and an equivalent bivariate normal model for the logit transforms of sensitivity and specificity between studies (16) . To evaluate the robustness of our results with outlying studies a sensitivity analysis was performed excluding studies one at a time (leaveone-study-out approach). All analyses were performed in 
RESULTS
The sensitivity analysis included eleven studies ofTST (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , 10 ofQFT-G-IT (17) (18) (19) (20) (21) (22) (24) (25) (26) (27) , and 9 of the T-SPOT.TB (17, 18, 20, 21, (23) (24) (25) 28, 29) . The specificity analysis included eight studies of TST (17, 19, (20) (21) (22) (23) (24) (25) ,8 ofQFT-G-IT (17, (19) (20) (21) (22) (25) (26) (27) , and 7 of the T-SPOT.TB (17, 20, 21, (23) (24) (25) 29) , as summarized in Fig. 1 . In four studies reporting TST results relative to more than one cut off, data were extracted referring to the>10 mm cut off (17, (20) (21) (22) .
QFT-G-IT sensitivity ranged from 0.583 to 0.955 (meta-analytic estimate: 0.791, 95%CI: 0.696 to 0.885, Q test p-value <0.0001, F=75%); T-SPOT. TB sensitivity ranged from 0.500 to 0.950 (metaanalytic estimate: 0.741, 95%CI: 0.586 to 0.986, Q test p-value=O.OOI, F=92%); and TST sensitivity range was 0.517 to 0.983 (meta-analytic estimate: 0.823, 95%CI: 0.715 to 0.931, Q test p-value=O.OOI, F=89%).
QFTspecificityranged from 0.885 to 0.983 (metaanalytic estimate: 0.952, 95%CI: 0.931 to 0.974, Q test p-value =0.588, F »0%); T-SPOT.TB specificity ranged from 0.833 to 0.993 (meta-analytic estimate: 0.960, 95%CI: 0.926 to 0.995, Q test p-value=0.121, F=41%); and TST specificity range was 0.402 to 0.970 (meta-analytic estimate: 0.830, 95%CI: 0.744 to 0.916, Q test p-value < 0.001, F=89%) (Figs. 2 and 3). Statistically significant heterogeneity was evident in sensitivity and TST specificity analyses.
Sub-analysis in culturally corifirmed cases
Data regarding culturally confirmed cases were available in 6 studies including 112 children for QFT-G-T (17-19, 21, 26, 27) , six studies including 124 children for T-SPOT.TB (17, 18, 21, 23, 28, 29) , and eight studies including 165 children for TST (17) (18) (19) 21, 23, (26) (27) (28) .
The meta-analytic estimate for sensitivity was: 0.737 (05%CI: 0.576 to 0.897) for T-SPOT.TB, 0.897 (95%CI:0.834 to 0.960) for QFT-G-IT, and 0.857 (95%CI: 0.761 to 0.954) for TST.
DISCUSSION
Our meta-analytic results showed no better sensitivity of QFT-G-IT and T-SPOT.TB than TST, but a higher specificity of IGRAs. In the subgroup of microbiologically confirmed cases sensitivity increased for QFT-G-IT and TST, reaching 89.7% and 85.7%, but it was substantially unchanged (73.7%) for T-SPOT.TB. However, confidence intervals were wide and no statistical difference was observed. Paediatric data are rapidly accumulating. The majority of the studies included were published in 2008-2010, and data are now sufficient to allow us to aggregate results from paediatric studies. Due to (6, 7, 30) . In 2010 two other metaanalyses were published regarding active TB cases, including adult and paediatric studies, but pooled sub-analysis in children was not carried out (5, 31) .
Results from other meta-analyses reported a TST sensitivity of 70% (95%CI: 67 to 72) (5) and 77% (95%CI: 71 to 82) (7) , which were similar to ours. Both ours and Pai's sensitivity (7) are within the commonly reported sensitivity range for TST (75-90%) (1). Conversely, Die1's results seemed to be particularly low and have been ascribed by the authors to the tightened study inclusion criteria (5) . Obviously, results may be variably influenced by many factors, including differences in population age, proportion ofBCG vaccinated subjects, settings, and variable TST cut-off values. In our study the pooled QFT-G-IT and T-SPOT. TB sensitivities are similar (79.1% vs 74.1%) and confidence limits overlap. In two previous metaanalyses in adults, ELISPOT sensitivity was reported to be superior to that of QFT-G/QFT-G-IT: 0.81 for QFT-G/QFT-G-IT vs 0.88 for ELISPOT (5) , and 0.70-0.78 for QFT-G/QFT-G-IT vs 0.90 for ELISPOT (7), while no difference was observed by Sester and colleagues who reported a sensitivity of 80% for QFT-G-IT, and 81% for T-SPOT.TB (31) .
In our meta-analysis, the sensitivity of T SPOT. TB was substantially lowered by the results of two recent large UK studies (17, 18) and by Nicol's study conducted in South Africa (23) . Besides technical errors and specimen handling issues, immunophysiological reasons for the lower T-SPOT. TB sensitivity in children have been suggested (17) . The initial immune responses might be (32) and, likely, there are insufficient numbers of effector T lymphocytes in the peripheral circulation to be measurable by the T.SPOT.TB. In the sub-analysis including only microbiologically confirmed cases, sensitivity of TST and QFT-G-IT increased to 85.7 and 89.7% but T-SPOT.TB sensitivity was unchanged and remained at 73.7%. However, the limited dataset available for the analysis led to wide 95% confidence limits (0.576-0.897). Thus, we believe that this subanalysis should be considered with caution.
Pooled TST specificity in our study was lower than QFT-G-IT and T-SPOT.TB specificity. This may be due to false positive results in BCG vaccinated children (4) . However, a metaregression analysis failed to demonstrate a correlation between proportions of BCG vaccinated children and TST specificity (data not shown).
In our study IGRA specificity was similar to that reported in previous meta-analyses (5, 7) . Only in Sester's meta-analysis (31) IGRA specificity was much lower, being 59% for T-SPOT.TB and 79% for QFT-G-IT. Like Sester and colleagues, we extracted specificity data from studies that assessed IGRA performance not in low risk controls but in TB suspects, as these subjects are more representative of patients that would actually be tested in the clinical setting. However, IGRA specificity obtained in our study was in line with findings from previous meta-analysis (5, 7) and not with Sester's results and clearly demonstrated a higher IGRA specificity in respect to TST in children.
Our results are consistent with those of a previous pediatric meta-analysis, showing overall QFT-G sensitivity of 66% (95%CI:54-78), reaching 70% (95%CI: 53-84%) in low incidence settings (1) . However performance of T-SPOT.TB was not evaluated (1) .
Our study has some limitations. Since microbiological confirmation of active tuberculosis is exceptional in children (17), we decided to include both microbiologically confirmed cases and cases diagnosed on clinical and radiological bases. Otherwise, the majority of paediatric cases would have been excluded. This may have also contributed to the high heterogeneity observed. For this reason we perfonned a sub-analysis including only microbiologically confirmed cases, but dataset was limited and we believe that this issue should be considered when interpreting our results.
It should also be considered that the sensitivity calculated for active disease cases may not necessarily be the same as that for latent TB infection. Diel has suggested that IGRA sensitivity for detecting latent tuberculosis infection may be higher than that observed for active TB (5) .
We found considerable heterogeneity among studies reflecting clinical heterogeneity of the various study settings and populations. To optimize the analysis, studies including less than ten children (33) (34) (35) or studies prevalently conducted on children with immunodeficiency were excluded (23, (36) (37) (38) (39) (40) . Our results might not be generalisable to developing countries where IGRA performances might be inferior possibly due to weak immune response in children malnourished or with co-morbidities (8, 41) . In these settings considerations regarding costs, ease of use for clinicians and other health workers, patient acceptability, ease of distribution and storage should also be taken into account. Finally, it was not possible to perform a sub-analysis considering IGRA performance in relationship to children's age. Available data in young children are discordant and insufficient to draw a conclusion regarding IGRA performance in young children (17, 23, 26, 42) .
In conclusion, according to our results, IGRAs show good promise for improving TB diagnosis in children. IGRAs are as sensitive, and more specific than TST in distinguishing TB infection from infection due to non-tuberculosis mycobacteria or previous BCG vaccination. Although encouraging, IGRA sensitivity is 74-79%, indicating that neither tests may rule out nor confirm the certainty of diagnosis and, similarly to the TST, interpretation of results may be difficult. As recently recommended by the American Academy of Paediatrics (9), paediatricians while deciding who deserves antitubercular therapy, still have to consider clinical and epidemiological data. Some authors suggest that the combined use of TST and IGRAs might help clinicians by increasing the diagnostic sensitivity to 90% (18) .
